Intellia Therapeutics (NTLA) Misses Q4 EPS by 1c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Intellia Therapeutics (NTLA) Misses Q4 EPS by 1c, Revenues Beat

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

February 27, 2020 7:30 AM EST

On track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T cell therapy, for the treatment of acute myeloid leukemia in 1H 2021Expects to nominate a development candidate for the treatment of hereditary angioedema in 1H 2020Ends 2019 with a strong cash position of $284 million; cash runway through YE 2021

CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:... More